We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+63.98%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.82B
AUM Growth
+$494M
Cap. Flow
-$97.3M
Cap. Flow %
-5.34%
Top 10 Hldgs %
79.12%
Holding
32
New
–
Increased
1
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
XFOR icon
X4 Pharmaceuticals
XFOR
+$4.47M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$50.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$30.4M
3
INZY
Inozyme Pharma
INZY
+$9.75M
4
CELC icon
Celcuity
CELC
+$6M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 91.73%
2 Consumer Staples 8.27%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.27B
$294M 16.13%
2,909,956
– –
ACLX
2
DELISTED
Arcellx
ACLX
$250M 13.72%
3,045,262
-700,000
-19% -$50.4M
VRNA
3
DELISTED
Verona Pharma
VRNA
$240M 13.19%
2,252,994
-10,144
-0.4% -$1.06M
COUR icon
4
Coursera
COUR
$1.58B
$151M 8.27%
12,867,769
– –
TRVI icon
5
Trevi Therapeutics
TRVI
$2.49B
$121M 6.64%
13,222,228
– –
CELC icon
6
Celcuity
CELC
$4.4B
$106M 5.81%
2,144,261
-150,000
-7% -$6M
SVRA icon
7
Savara
SVRA
$1.13B
$87.4M 4.79%
24,471,264
– –
CRSP icon
8
CRISPR Therapeutics
CRSP
$4.68B
$68.6M 3.76%
1,058,570
-529,284
-33% -$30.4M
MBX
9
MBX Biosciences
MBX
$2.89B
$63.3M 3.47%
3,614,486
– –
ZBIO
10
Zenas BioPharma
ZBIO
$1.97B
$60.7M 3.33%
2,733,719
– –
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$2.02B
$57M 3.13%
7,692,298
– –
KRRO icon
12
Korro Bio
KRRO
$166M
$52.2M 2.87%
1,090,793
– –
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.1B
$49.4M 2.71%
4,118,621
– –
GOSS icon
14
Gossamer Bio
GOSS
$72.5M
$47.6M 2.61%
18,093,034
– –
AUPH icon
15
Aurinia Pharmaceuticals
AUPH
$1.98B
$43.9M 2.41%
3,969,834
– –
PHAT icon
16
Phathom Pharmaceuticals
PHAT
$856M
$23.1M 1.27%
1,960,169
– –
NEUE
17
DELISTED
NeueHealth
NEUE
$18.2M 1%
2,726,917
– –
BDTX icon
18
Black Diamond Therapeutics
BDTX
$103M
$16.9M 0.93%
4,448,757
– –
CVRX icon
19
CVRx
CVRX
$125M
$16.4M 0.9%
2,026,083
– –
CSBR icon
20
Champions Oncology
CSBR
$85.1M
$11.1M 0.61%
1,713,720
– –
IVA
21
Inventiva
IVA
$1.07B
$8.32M 0.46%
1,462,586
– –
OMDA
22
Omada Health Inc
OMDA
$1.42B
$8.05M 0.44%
364,115
– –
XFOR icon
23
X4 Pharmaceuticals
XFOR
$346M
$7.64M 0.42%
2,233,743
+1,734,184
+347% +$4.47M
NKTX icon
24
Nkarta
NKTX
$186M
$7.39M 0.41%
3,568,781
– –
SNTI icon
25
Senti Biosciences Holdings
SNTI
$13.3M
$5.32M 0.29%
3,775,615
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.76B AUM 18.21% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
PCA
Prosperity Capital Advisors Westlake, Ohio $1.76B AUM 18.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.76B AUM 15.32% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return

NEA Management Company's Q3 2025 Portfolio in Review

As of Q3 2025, NEA Management Company held 32 positions worth $1.82B, up 37% from $1.33B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

NEA Management Company withdrew a net $97.3M in Q3 2025, closing 3 positions and reducing 4 holdings. Its most notable exit was Inozyme Pharma, an estimated $9.75M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, NEA Management Company added an estimated $4.47M to X4 Pharmaceuticals.

  • NEA Management Company added most to X4 Pharmaceuticals in Q3 2025, an estimated $4.47M increase.
  • NEA Management Company's biggest Q3 2025 reduction was Arcellx, cutting an estimated $50.4M.
  • NEA Management Company fully exited Inozyme Pharma in Q3 2025, selling an estimated $9.75M.
  • NEA Management Company's ten largest holdings make up 79% of its $1.82B portfolio in Q3 2025.
  • NEA Management Company opened 0 new positions and closed 3 in Q3 2025.
  • NEA Management Company's portfolio value rose 37% quarter-over-quarter to $1.82B.

Based on NEA Management Company's 13F filing for Q3 2025, filed 14 Nov 2025.